

해외 바이오의약품 임상 현황 (2020.04.27~2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

○ 미국 62건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04372706	RTX-240 Monotherapy	Solid Tumor, Adult	Drug: RTX-240	Rubius Therapeutics	Phase 1 Phase 2
NCT04285671	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Necitumumab Drug: Osimertinib Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Trastuzumab	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Eli Lilly and Company Genentech, Inc.	Phase 1 Phase 2
NCT04257578	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma	B-Cell Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Primary Mediastinal (Thymic) Large B-Cell Lymphoma Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Drug: Acalabrutinib Biological: Axicabtagene Ciloleucel	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 1 Phase 2
NCT04220775	M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer	Recurrent Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Arising in a Previously Radiated Region	Drug: Bintrafusp Alfa Other: Quality-of-Life Assessment Other: Questionnaire Administration Radiation: Stereotactic Body Radiation Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04074967	Study of ARRY-614 Plus Either Nivolumab or Ipilimumab	Renal Cell Carcinoma Melanoma Solid Tumor	Drug: Phase Ib ARRY-614 + nivolumab Drug: Phase Ib ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + nivolumab (melanoma) Drug: Phase II ARRY-614 + nivolumab (RCC)	Jason J. Luke, MD Array BioPharma University of Pittsburgh	Phase 1 Phase 2
NCT03597594	Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Severe Combined Immunodeficiency	Drug: Anti-thymocyte globulin (rabbit) Drug: Busulfan Drug: Fludarabine Drug: Thiotepa Device: CliniMACS Other: Donor Lymphocyte Infusion	St. Jude Children's Research Hospital	Phase 1 Phase 2
NCT04367077	MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)	ARDS	Biological: MultiStem Biological: Placebo	Athersys, Inc	Phase 2 Phase 3
NCT04369937	HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma	HPV-Related Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma	Radiation: IMRT (Intensity Modulated Radiotherapy) Drug: Pembrolizumab Drug: Cisplatin Biological: ISA101b	Robert Ferris Merck Sharp & Dohme Corp. ISA Pharmaceuticals University of Pittsburgh	Phase 2
NCT04357587	Safety and Feasibility of PD-1 Blockade in the Treatment of Rectal Cancer	Rectal Neoplasms	Drug: Pembrolizumab Radiation: External beam radiation Drug: Capecitabine	Case Comprehensive Cancer Center	Phase 1
NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	SARS-CoV 2	Drug: Tocilizumab Drug: Placebos	Massachusetts General Hospital Genentech, Inc.	Phase 3
NCT04355767	Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19	COVID-19	Biological: Convalescent Plasma Biological: Standard Plasma	Stanford University	Phase 2
NCT04352205	Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure	Plasma Cell Myeloma Renal Failure	Drug: Bortezomib Biological: Daratumumab Drug: Dexamethasone Drug: Lenalidomide Drug: Thalidomide	Emory University Janssen Scientific Affairs, LLC National Cancer Institute (NCI)	Phase 2
NCT04339062	Cemiplimab in AlloSCT/SOT Recipients With CSCC	Cutaneous Squamous Cell Carcinoma Advanced Cancer	Drug: Cemiplimab Drug: Everolimus Drug: Sirolimus Drug: Prednisone	Dana-Farber Cancer Institute Regeneron Pharmaceuticals	Phase 1
NCT04337827	Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder	Post-transplant Lymphoproliferative Disorder	Drug: Rituximab Drug: Acalabrutinib Diagnostic Test: CT scans	Deepa Jagadeesh Case Comprehensive Cancer Center	Phase 2
NCT04331275	Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant	Solid Organ Transplant Viral Infection	Biological: Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2
NCT04326257	Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy	Squamous Cell Carcinoma of the Head and Neck	Drug: Nivolumab+Relatlimab Drug: Nivolumab+Ipilimumab	Dan Zandberg Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6352	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2
NCT04297605	Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2	Non-small Cell Lung Cancer	Drug: Pembrolizumab Other: Pemetrexed (Chemotherapy) Other: Nab-paclitaxel (Chemotherapy)	University of Rochester	Phase 1
NCT04288856	Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BII078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: BII078	Biogen	Phase 1
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease	Drug: Fecal Microbiota Transplantation Capsule	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2

해외 바이오의약품 임상 현황 (2020.04.27 ~ 2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

NCT04236479	Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)	Congenital Heart Disease (CHD)	Biological: BM-MSC	Catherine Bollard Children's National Research Institute	Phase 1
NCT04216524	SL401, Venetoclax, and HCVAD Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm	Blastic Plasmacytoid Dendritic Cell Neoplasm	Drug: Cyclophosphamide Drug: Cytarabine Drug: Dexamethasone Drug: Doxorubicin Drug: Mercaptopurine Drug: Methotrexate Drug: Methylprednisolone Drug: Prednisone Biological: Rituximab Biological: Tagraxofusp-erz Drug: Venetoclax Drug: Vincristine	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04205409	Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma	Biological: Nivolumab	University of Washington National Cancer Institute (NCI) Bristol-Myers Squibb	Phase 2
NCT04171622	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Metastatic Thyroid Gland Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 Thyroid Gland Squamous Cell Carcinoma Unresectable Thyroid Gland Carcinoma	Drug: Lenvatinib Biological: Pembrolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04163419	Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis	Schwannomatosis Pain	Drug: Tanezumab Drug: Placebo	Massachusetts General Hospital Pfizer	Phase 2
NCT04153422	IVIg in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS or FGFR-3 Antibodies	Small Fiber Neuropathy Autoimmune Small Fiber Neuropathy Inflammatory Polyneuropathy Immune-Mediated Neuropathy	Drug: Gammagard IVIG Drug: Placebo	Loyola University Takeda	Phase 2
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison Ipser	Phase 2
NCT04149275	Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma	Carcinosarcoma of Ovary Carcinosarcoma of Uterus Carcinosarcoma of Vagina	Drug: Cabozantinib Drug: Ipilimumab Drug: Nivolumab	University of Alabama at Birmingham	Phase 2
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Non Small Cell Lung Cancer Advanced Solid Tumor Metastatic Melanoma Metastatic Head and Neck Carcinoma Metastatic Renal Cell Carcinoma Metastatic Colorectal Cancer Sarcomas Metastatic Prostate Cancer	Drug: ONC-392 Drug: Pembrolizumab	OncoImmune, Inc.	Phase 1
NCT04139902	PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)	Melanoma Stage III Melanoma Stage IV	Drug: Dostarlimab (TSR-042) (singly) Drug: Dostarlimab (TSR-042) and TSR-022 (combination)	Diwakar Davar Tesarro, Inc. University of Pittsburgh	Phase 2
NCT04114136	Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Melanoma Renal Cell Carcinoma NSCLC Hepatocellular Carcinoma Urothelial Cancer Gastric Adenocarcinoma HNSCC Esophageal Adenocarcinoma Microsatellite Instability-High Solid Malignant Tumor	Drug: Nivolumab or Pembrolizumab (dependent upon approved indication) Drug: Metformin Drug: Rosiglitazone	Dan Zandberg University of Pittsburgh	Phase 2
NCT04061980	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	BRAF NP_004324.2:p.V600M BRAF V600E Mutation Present Metastatic Thyroid Gland Carcinoma Refractory Thyroid Gland Carcinoma Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab	Providence Health & Services	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agiros Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04015700	Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Glioblastoma	Biological: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics Device: CELLECTRA®2000 EP Device supplied by Geneos Therapeutics Drug: Plasmid encoded IL-12	Washington University School of Medicine Novio Pharmaceuticals	Phase 1
NCT04006652	ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients	Acute Graft Versus Host Disease Haploidentical Hematopoietic Stem Cell Transplant	Drug: ApoGraft	Washington University School of Medicine Cellect Biotechnology	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03818763	Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A	Hemophilia A	Biological: Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII	Parameswaran Hari Medical College of Wisconsin	Phase 1

해외 바이오의약품 임상 현황 (2020.04.27 ~ 2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

NCT03679624	Daratumumab Plus Ibrutinib in Patients With Waldenström's Macroglobulinemia	Waldenstrom Macroglobulinemia[Waldenstrom's Disease]Waldenström; Hypergammaglobulinemia[Waldenstrom's Macroglobulinemia Recurrent]Waldenstrom's Macroglobulinemia of Lymph Nodes[Waldenstrom's Macroglobulinaemia, Without Mention of Remission]Waldenstrom's Macroglobulinemia Refractory	Drug: Ibrutinib[Drug: Daratumumab	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC Mayo Clinic	Phase 2
NCT03678545	Dupilumab in Eosinophilic Gastritis	Eosinophilic Gastritis[Eosinophilic Gastroenteritis	Drug: Dupilumab (blinded)[Drug: Placebo (blinded)]Drug: Dupilumab (open-label)	Children's Hospital Medical Center, Cincinnati Regeneron Pharmaceuticals	Phase 2
NCT03552796	sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	Recurrent Bladder Carcinoma Bladder Cancer Stage 0 Bladder Cancer Stage I	Other: Pharmacokinetic Study Biological: Recombinant EphB4-HSA Fusion Protein	University of Southern California National Cancer Institute (NCI)	Phase 1
NCT03219450	A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.	Lymphocytic Leukemia	Drug: NeoVax[Drug: Cyclophosphamide	Dana-Farber Cancer Institute Oncovir, Inc. Neon Therapeutics, Inc.	Phase 1
NCT03203525	Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	Advanced Malignant Neoplasm Colorectal Carcinoma Metastatic in the Liver Metastatic Malignant Neoplasm in the Liver Refractory Malignant Neoplasm	Biological: Bevacizumab[Drug: Fluorouracil][Drug: Leucovorin][Drug: Oxaliplatin][Drug: Pegylated Liposomal Doxorubicin Hydrochloride][Drug: Temsirolimus]Procedure: Tumor Treating Fields Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT03058068	Human Mesenchymal Stem Cells Infusion in Patients With Cystic Fibrosis	Cystic Fibrosis	Biological: Allo-hMSCs Biological: Placebo	Joshua M Hare University of Miami	Phase 1
NCT02962661	Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines	Cardiomyopathy Heart Failure	Other: Best Practice Other: Laboratory Biomarker Analysis Biological: Mesenchymal Stem Cell Transplantation	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04148352	Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy	Allergies Food Milk	Drug: Dupilumab Other: Placebo	Andrew J Long, PharmD Stanford University	Phase 2
NCT04118036	Abemaciclib + Pembrolizumab In Glioblastoma	Glioblastoma	Drug: Pembrolizumab[Drug: Abemaciclib	Dana-Farber Cancer Institute	Phase 2
NCT03920878	Cataract DME - Peri vs. Intraop	Diabetic Macular Edema Cataract	Drug: Aflibercept injected Pre- and Post-operatively[Drug: Aflibercept injected intraoperatively	Emory University	Phase 2
NCT04269265	The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Vaccination	Yellow Fever	Biological: Yellow Fever Vaccine	University of Minnesota National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 Phase 2
NCT04246177	Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)	Carcinoma, Hepatocellular	Drug: Lenvatinib Biological: Pembrolizumab[Drug: Oral Placebo][Drug: IV Placebo]Procedure: TACE	Merck Sharp & Dohme Corp. Eisai Inc.	Phase 3
NCT04375228	Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)	Immune-related Adverse Events Advanced Solid Tumor	Drug: Rituximab[Drug: Tocilizumab	Columbia University Genentech, Inc.	Phase 2
NCT04361162	Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer	Pancreatic Cancer Metastatic Pancreatic Cancer	Drug: Nivolumab[Drug: Ipilimumab]Radiation: Radiation	Massachusetts General Hospital Bristol-Myers Squibb	Phase 2
NCT04356729	A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	Clinical Stage III Cutaneous Melanoma AJCC v8 Stage IV Melanoma Unresectable Stage III Cutaneous Melanoma Unresectable Stage IV Cutaneous Melanoma	Drug: Atezolizumab[Drug: Bevacizumab	Elizabeth Buchbinder Genentech, Inc. Dana-Farber Cancer Institute	Phase 2
NCT04266275	Topical Curcumin for HPV Related Cervical Disease	Neoplasm Cervix	Drug: Curcumin C3 Complex[Drug: Placebo	Lisa Flowers Emory University	Phase 2
NCT04227938	Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease	Graft Vs Host Disease	Drug: ALPN-101	Alpine Immune Sciences, Inc.	Phase 1
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab Other: Placebo	Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen	Phase 2
NCT04368728	Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults	SARS-CoV-2 Infection COVID-19	Biological: BNT162a1 Biological: BNT162b1 Biological: BNT162b2 Biological: BNT162c2 Other: Placebo	Biontech SE Pfizer	Phase 1
NCT04213274	Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome	Schnitzler Syndrome Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)	Biological: 80 mg RPH-104[Drug: Placebo	R-Pharm Overseas, Inc. Worldwide Clinical Trials R-Pharm	Phase 2
NCT04171843	A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma	Relapsed/Refractory Multiple Myeloma	Genetic: PBCAR269A[Drug: Fludarabine][Drug: Cyclophosphamide	Precision BioSciences, Inc.	Phase 1 Phase 2

해외 바이오의약품 임상 현황 (2020.04.27 ~ 2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

NCT04371393	MSCs in COVID-19 ARDS	Mesenchymal Stromal Cells Remestemcel-L	Biological: Remestemcel-L® Drug: Placebo	Icahn School of Medicine at Mount Sinai Mesoblast, Inc.	Phase 3
NCT04145193	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC	Microsatellite-stable Colorectal Cancer	Drug: Standard of Care - mFOLFOX6 Drug: E1 - mFOLFOX and durvalumab Drug: E2 - mFOLFOX6, durvalumab and olectumab Drug: E3 - mFOLFOX6, durvalumab and monalizumab	MedImmune LLC	Phase 2
NCT04209660	Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Adenoid Cystic Carcinoma Salivary Gland Cancer	Drug: Lenvatinib Drug: Pembrolizumab	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme Corp. Eisai Inc.	Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04359654	Nebulised Dornase Alfa for Treatment of COVID-19	COVID19 Hypoxia	Drug: Dornase Alfa Inhalation Solution [Pulmozyme]	University College, London	Phase 2

○ 프랑스 10건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04371367	Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia (FORCE)	COVID	Biological: avdoralimab Other: Placebo	Assistance Publique Hopitaux De Marseille Innate Pharma	Phase 2
NCT04133233	Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder	Bipolar Depression	Drug: ILT101 Drug: Placebos	Assistance Publique - Hôpitaux de Paris Ilto Pharma	Phase 2
NCT03968198	Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia	Critical Limb Ischemia and Peripheral Artery Disease	Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)	University Hospital, Toulouse Institut National de la Santé Et de la Recherche Médicale, France Etablissement Français du Sang	Phase 2
NCT04372979	Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.	COVID-19	Drug: Transfusion of SARS-CoV-2 Convalescent Plasma Drug: Transfusion of standard Plasma.	Direction Centrale du Service de Santé des Armées University Hospital, Grenoble	Phase 3
NCT04274023	Study on TSR-042 in Advanced Clear Cell Sarcoma	Sarcoma, Clear Cell	Drug: TSR-042	Italian Sarcoma Group GlaxoSmithKline	Phase 2
NCT04348045	Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients	Metastatic Pancreatic Adenocarcinoma	Drug: Arm A - Olaparib Drug: ARM B - durvalumab plus selumetinib Drug: ARM C FOLFIRI	GERCOR - Multidisciplinary Oncology Cooperative Group AstraZeneca	Phase 2
NCT04262687	Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate	Colorectal Cancer Metastatic High Immune Infiltrate Microsatellite Stable	Drug: Capecitabine Drug: Oxaliplatin Drug: Bevacizumab Drug: Pembrolizumab	Federation Francophone de Cancerologie Digestive	Phase 2
NCT04239196	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Giant Cell Arteritis Optic Ischaemic Neuropathy	Drug: tocilizumab and IV steroids combination Other: IV steroids combination alone	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Roche Chugai	Phase 2
NCT04108026	Immunotherapy in Patient With Poor General Condition	Non-small Cell Lung Cancer Stage IV	Drug: Durvalumab	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
NCT04145193	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC	Microsatellite-stable Colorectal Cancer	Drug: Standard of Care - mFOLFOX6 Drug: E1 - mFOLFOX and durvalumab Drug: E2 - mFOLFOX6, durvalumab and olectumab Drug: E3 - mFOLFOX6, durvalumab and monalizumab	MedImmune LLC	Phase 2

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04119440	Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF1	MERS (Middle East Respiratory Syndrome)	Biological: MVA-MERS-S_DF1 - Low Dose Biological: MVA-MERS-S_DF1 - High Dose Other: Placebo	Universitätsklinikum Hamburg-Eppendorf Coalition for Epidemic Preparedness Innovations DT Biologika Dessau.Rossau German Center for Infection Research CR2O Clinical Trial Center North (CTC North GmbH & Co. KG) Erasmus Medical Center	Phase 1
NCT04231981	Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)	Penile Cancer	Drug: INCMGA0012	MedSIR Incyte Corporation	Phase 2
NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	COVID-19	Drug: RhACE2 APN01 Drug: Physiological saline solution	Apeiron Biologics	Phase 2

해외 바이오의약품 임상 현황 (2020.04.27~2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

○ 중국 24건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04284488	Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors	Advanced Solid Tumor	Drug: APG-1387 for Injection Drug: Toripalimab	Ascentage Pharma Group Inc.	Phase 1 Phase 2
NCT04148742	Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)	Non-Hodgkin's B-cell Lymphoma	Drug: DZD9008	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Phase 1 Phase 2
NCT04146298	Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer	Pancreatic Cancer Pancreatic Neoplasms Pancreatic Ductal Adenocarcinoma Advanced Cancer	Drug: Cyclophosphamide Drug: Fludarabine Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells Drug: Anti-PD-1 monoclonal antibody	Guo ShiWei Providence Cancer Center, Earle A. Chiles Research Institute Changhai Hospital	Phase 1 Phase 2
NCT04373967	Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes	Type 2 Diabetes	Drug: Victoza® Drug: Metformin Hydrochloride Drug: TQZ2451	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
NCT04371185	Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects	Psoriasis	Drug: BAT2206 Drug: Stelara(US-licensed) Drug: Stelara(EU-licensed)	Bio-Thera Solutions	Phase 1
NCT04370379	Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients	Neovascular Age-related Macular Degeneration	Drug: IBI302 (the first dose level) Drug: IBI302 (the second dose level) Drug: Aflibercept	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04367025	Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer	Gastric Cancer	Drug: Camrelizumab Drug: Oxaliplatin Drug: S1	Chinese PLA General Hospital	Phase 2
NCT04363359	Clinical Trial of Quadrivalent Influenza Virus Split Vaccine	Influenza	Biological: 0.5ml Quadrivalent influenza vaccine Biological: 0.25ml Quadrivalent influenza vaccine Biological: 0.25ml Trivalent influenza vaccine(B/V) Biological: 0.25ml Trivalent influenza vaccine(B/Y)	Shanghai Institute Of Biological Products	Phase 2
NCT04358432	A Phase II Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia	Hypercholesterolemia	Drug: AK102 Drug: Placebos Drug: Statins and/or Ezetimibe	Akeso AD Pharmaceuticals Co., Ltd. (Guangzhou)	Phase 2
NCT04357509	The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma	Melanoma	Biological: Super circulating tumor infiltrating lymphocytes(ScTIL)	Beijing Cancer Hospital	Phase 1
NCT04355858	Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer	Breast Neoplasm	Drug: SHR7390 Drug: Famitinib Drug: SHR3162 Drug: Pyrotinib Drug: Capecitabine Drug: SHR1210 Drug: Everolimus Drug: Nab paclitaxel Drug: SHR2554 Drug: SHR3680 Drug: SHR6390 Drug: SHR1701	Fudan University	Phase 2
NCT04351308	Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma	Osteosarcoma Survival Chemotherapy Effect Toxicity, Drug	Drug: MAPI chemotherapy Drug: Apatinib Mesylate Drug: Camrelizumab	Peking University People's Hospital Chinese Sarcoma Study Group	Phase 2
NCT04340167	Study of Anti-CD22 CAR-T Cells Treating Leukemia Children	Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia	Biological: Autologous humanized anti-CD22 chimeric antigen receptor T cells	Beijing Boren Hospital	Phase 2
NCT04340154	Study of Sequential CAR-T Cell Treating Leukemia Children	Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoid Leukemia	Biological: chimeric antigen receptor T cell	Beijing Boren Hospital	Phase 2
NCT04325841	Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children	Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia	Biological: Murine autologous anti-CD19 chimeric antigen receptor T cells	Beijing Boren Hospital	Phase 2
NCT04294784	Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer	Gastric Cancer GastroEsophageal Cancer	Drug: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor) Drug: Albumin-bound Paclitaxel	Huazhong University of Science and Technology	Phase 2
NCT04278859	Safety, Tolerability and Pharmacokinetics of a a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies of China	Advanced Solid Tumor	Biological: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion	Shanghai Junshi Bioscience Co., Ltd.	Phase 1
NCT04175847	A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors	Solid Tumor	Drug: RC88	RemeGen	Phase 1
NCT04099303	Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .	Diphtheria Tetanus Pertussis	Biological: Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed Biological: Diphtheria-tetanus-acellular pertussis vaccine Biological: Diphtheria,tetanus,pertussis(acellular,com ponent),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine	CanSino Biologics Inc. Henan Center for Disease Control and Prevention	Phase 1

해외 바이오의약품 임상 현황 (2020.04.27 ~ 2020.05.03)

한국바이오의약품협회, 2020.5.6.
출처: ClinicalTrials.gov

NCT03944239	Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa	Retinitis Pigmentosa	Biological: Retinal pigment epitheliums transplantation	Qi Zhou Beijing Tongren Hospital Chinese Academy of Sciences	Phase 1
NCT02968459	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars	Uterine Scar	Other: Umbilical cord MSCs Other: 0.9% Saline	Maternal and Child Health Hospital of Foshan	Phase 2
NCT04363255	First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC	Small Cell Lung Carcinoma	Drug: Etoposide Injection Drug: Carboplatin Injection Drug: Cisplatin injection Drug: Toripalimab Drug: Anlotinib hydrochloride	Taizhou Hospital	Phase 2
NCT04350190	Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	Drug: Apatinib mesylate tablet Drug: PD-1	Wei Jiang Wuzhou Red Cross Hospital Guangxi Naxishan Hospital People's Hospital of Laibin People's Hospital of Lingshan Guilin Medical University, China	Phase 2
NCT04344158	A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)	Advanced Hepatocellular Carcinoma (HCC)	Drug: AK105 Injection Drug: Anlotinib Hydrochloride Capsules Drug: Sorafenib Tosylate Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04355117	A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients	Migraine	Drug: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.	Otsuka Pharmaceutical Co., Ltd.	Phase 3
NCT04210843	Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab	Chronic Spontaneous Urticaria	Drug: Ligelizumab	Novartis Pharmaceuticals Novartis	Phase 3